Macrocyclic peptidomimetic protease inhibitor and use thereof
US-2024327458-A1 · Oct 3, 2024 · US
Smarca degraders and uses thereof
US2025109138A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2025109138-A1 |
| Application number | US-202118265604-A |
| Country | US |
| Kind code | A1 |
| Filing date | Dec 9, 2021 |
| Priority date | Dec 9, 2020 |
| Publication date | Apr 3, 2025 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides compounds, compositions thereof, and methods of using the same.
First claim
Opening claim text (preview).
1 - 30 . (canceled) 31 . A compound selected from: or pharmaceutically acceptable salt thereof. 32 . The compound of claim 31 , said compound selected from: or pharmaceutically acceptable salt thereof. 33 . The compound of claim 31 , said compound selected from: or pharmaceutically acceptable salt thereof. 34 . The compound of claim 31 , said compound selected from: or pharmaceutically acceptable salt thereof. 35 . The compound of claim 31 , said compound selected from: or pharmaceutically acceptable salt thereof. 36 . The compound of claim 31 , said compound selected from: or pharmaceutically acceptable salt thereof. 37 . A compound selected from: or pharmaceutically acceptable salt thereof. 38 . The compound of claim 37 , said compound selected from: or pharmaceutically acceptable salt thereof. 39 . The compound of claim 37 , said compound selected from: or pharmaceutically acceptable salt thereof. 40 . The compound of claim 37 , said compound selected from: or pharmaceutically acceptable salt thereof. 41 . The compound of claim 37 , said compound selected from: or pharmaceutically acceptable salt thereof. 42 . A compound selected from: or pharmaceutically acceptable salt thereof. 43 . The compound of claim 42 , said compound selected from: or pharmaceutically acceptable salt thereof. 44 . The compound of claim 42 , said compound selected from: or pharmaceutically acceptable salt thereof. 45 . The compound of claim 42 , said compound selected from: or pharmaceutically acceptable salt thereof. 46 . The compound of claim 42 , said compound selected from: or pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title
the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug · CPC title
- C07D487/08Primary
Bridged systems · CPC title
- C07D417/14Primary
containing three or more hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2025109138A1 cover?
- The present invention provides compounds, compositions thereof, and methods of using the same.
- Who is the assignee on this patent?
- Kymera Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D487/08. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Apr 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).